News & Updates
Filter by Specialty:
Jaktinib superior to hydroxyurea in myelofibrosis
Jaktinib, a novel JAK and AVCR1 inhibitor, is more effective than hydroxyurea in patients with myelofibrosis, resulting in better spleen response with improved symptom response and less cytopenias, according to the results of a phase III study presented at EHA 2023.
Jaktinib superior to hydroxyurea in myelofibrosis
07 Jul 2023
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
Use of renin-angiotensin system (RAS) inhibitors results in improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and advanced kidney disease, a study has shown.
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
06 Jul 2023
More evidence for COVID-19 vaccine safety in kids
COVID-19 vaccines can be safely administered in children, with a recent study showing that out of the numerous health outcomes monitored in near real time, the safety signal identified was for only myocarditis or pericarditis.
